1. Technical Field
The technical field of the invention is implantable medical devices, and in particular a stent useful for urinary drainage.
2. Background Information
Minimally-invasive surgery may be used in the removal of stones and calculi from kidneys and ureters. To treat this condition, several individual steps are involved. In one procedure, these steps include placing a relatively narrow guidewire through a urethra and a bladder and then through the ureter and into the kidney. After the guidewire is placed, a catheter is run along the guidewire, dilating the body passages (the urethra and the ureter) as it moves down the guidewire. In the next sequence for this procedure, a ureteral access sheath is guided along and down the guidewire and the catheter. The access sheath also dilates the body passages as it moves from outside the body, through the urethra, and into the ureter, down to the desired location, and into or very near the kidney.
The physician may then remove calculi and stones through the access sheath, using a grasper, a retrieval basket, or other device. The access sheath protects the ureter from repeated passage of the retrieval device while the stones or calculi are removed. After the stones are removed, a ureteral stent may be placed into the ureter through the access sheath, using the catheter or a pushing tube to position the stent. The stent is used to retain patency of the ureteral lumen and to continue normal urinary drainage.
One problem that is encountered with ureteral stents occurs in cancer patients, where a growth may apply radial compression to a ureter. Such compression can make fluid flow difficult. In these cases, a typical polymeric, relatively soft pig-tail stent may not have sufficient radial strength to resist compression by a cancerous or other growth. In these cases, a stronger, sturdier ureteral stent is needed to resist radial compression and allow for continued drainage from the kidney to the bladder. In some cases, a urethral stent or catheter may also be helpful to ensure drainage from the bladder.
A first representative embodiment is a stent. The stent includes a first coiled wire, which forms a first lumen defined by an inner surface collectively of each coil formed from the first coiled wire. The first coiled wire includes a distal end portion, a proximal end portion, and a central portion between the two end portions. The stent further includes a second coiled wire with an outer surface collectively of each coil formed by the second coiled wire. The second coiled wire forms a second lumen, is disposed within the first lumen of the first coiled wire, and is secured to the first coiled wire such that substantially the entire outer surface of the second coiled wire contacts substantially the entire inner surface of the first coiled wire. The second coiled wire includes a distal end portion, a proximal end portion, and a central portion between the two end portions. The first and second coiled wires are aligned with respect to each other so that the respective distal end portions, proximal end portions, and central portions of the first and second coiled wires are next to each other. The stent further includes apertures passing through each of the first and second coiled wires and into the second lumen. The apertures are located within the distal end, proximal end, and central portions of the first and second coiled wires.
A second representative embodiment is a stent. The stent includes a first coiled wire, which forms a first lumen between a distal end portion and a proximal end portion. The first coiled wire has an inner diameter and an outer diameter. The outer diameter is tapered at the distal end portion, and the inner diameter is constant at the distal end portion. The stent further includes a second coiled wire; which forms a second lumen, is disposed within the first lumen, and is secured to the first coiled wire such that substantially all of an outer surface of the second coiled wire contacts substantially all of an inner surface of the first coiled wire.
A third representative embodiment is a stent. The stent includes a first coiled wire, which forms a first lumen. The first coiled wire includes a distal end portion, a proximal end portion, and a central portion between the two end portions. The stent further includes a second coiled wire with an outer surface collectively of each coil formed by the second coiled wire. The second coiled wire forms a second lumen, is disposed within the first lumen, and is secured to the first coiled wire. The second coiled wire includes a distal end portion, a proximal end portion, and a central portion between the two end portions. The first and second coiled wires are aligned with respect to each other so that the respective distal end portions, proximal end portions, and central portions of the first and second coiled wires are next to each other. The stent further includes apertures passing through each of the first and second coiled wires and into the second lumen. The apertures are located within the distal end, proximal end, and central portions of the first and second coiled wires.
Another embodiment is a stent. The stent includes an outer sleeve, which forms a first lumen defined by an inner surface of the outer sleeve. The outer sleeve includes a distal end portion, a proximal end portion, and a central portion between the two end portions. The stent further includes an inner coiled wire with an outer surface collectively of each coil formed by the inner coiled wire. The inner coiled wire forms a second lumen, is disposed within the first lumen of the outer sleeve, and is secured to the outer sleeve such that substantially the entire outer surface of the inner coiled wire contacts substantially the entire inner surface of the outer sleeve. The inner coiled wire includes a distal end portion, a proximal end portion, and a central portion between the two end portions. The outer sleeve and the inner coiled wire are aligned with respect to each other so that the respective distal end portions, proximal end portions, and central portions of the outer sleeve and the inner coiled wire are next to each other. The stent further includes apertures passing through each of the outer sleeve and the inner coiled wire and into the second lumen. The apertures are located within the distal end, proximal end, and central portions of the first and second coiled wires.
The embodiments may also include least one pigtail defined by the distal end portion, the proximal end portion, or both end portions; a polymer coating infused with one of a pharmacological compound, a bioactive compound, or a biologic compound around an outer surface of the first coiled wire, with the apertures further passing through the polymer coating; and an outer diameter of the first coiled wire tapered at the distal end portion, the proximal end portion, or both end portions of the first coiled wire toward an end tip upon the distal end portion, the proximal end portion, or both end portions of the first coiled wire, and an inner diameter of the first coiled wire constant at the distal end portion, the proximal end portion, or both end portions of the first coiled wire.
There are many embodiments of the stents according to the present invention, of which only a few are described herein. The accompanying drawings and descriptions are mean to be illustrative rather than limiting.
Turning now to
The ureteral stent 1 may include a distal end portion 3, a proximal end portion 5, and a central portion 7 between the two end portions 3, 5. The end portions 3, 5 may be open for the passage of the ureteral stent 1 over a previously inserted wireguide (not shown) to its final location within the anatomy. The ureteral stent 1 also may include a plurality of apertures 9 (or a single aperture 9) that may be located within one or more of the distal end portion 3, the proximal end portion 5, and the central portion 7. The ureteral stent 1 may be constructed to be biased to define a pigtail 13 defined by the distal end portion 3, the proximal end portion 5, or both end portions 3, 5. The ureteral stent 1 also may include no pigtail 13. If the pigtail 13 is located on both end portions 3, 5, then the portion of the ureteral stent 1 between the pigtails 13 may preferably be about 4 cm to about 30 cm long. Other lengths may be used. While the pigtail 13 is depicted, one of ordinary skill in the art will understand that the ends of the ureteral stent 1 may define other shapes, such as a J, a curve, or an angle, that may be used to retain the ends of the ureteral stent 1 in the kidney and bladder, respectively.
Referring to
The second coiled wire 17 may be disposed within the first lumen 21 defined by the first coiled wire 15. The second coiled wire 17 may define the distal end portion 3, the proximal end portion 5, and the central portion 7 between the two end portions 3, 5, which may be aligned with the respective distal and proximal end portions 3, 5 and central portion 7 of the first coiled wire 15. The second coiled wire 17 may define a second lumen 11 therewithin.
The first and second coiled wires 15, 17 may be secured together such that substantially all of an outer surface 25 of the second coiled wire 17 may contact substantially all of an inner surface 23 of the first coiled wire 15 so that the second coiled wire 17 may be fixedly retained within first lumen 21. In the context of the outer surface 25 of the second coiled wire 17 contacting the inner surface 23 of the first coiled wire 15, “substantially” is defined as at least 75% of the surface area of the outer surface 25 of the second coiled wire 17 contacting the inner surface 23 of the first coiled wire 15. The first and second coiled wires 15, 17 may be longitudinally fixed together. The first and second coiled wires 15, 17 may be fixed together with one or more weld beads, mechanical fasteners, adhesives, press fit, or by other methods known to fix similar materials together. In some embodiments, both of the first and second coiled wires 15, 17 may be round wires, as shown in
The ureteral stent 1 further may be constructed to be biased to define deformable pigtails 13 defined by one or both of the distal and proximal end portions 3, 5 of the first and second coiled wires 15, 17 similar to the ureteral stent 1 shown in
An outer surface of the first coiled wire 15 may be coated, such as with a fluoropolymer or other protective, lubricious coating, to produce a polymer coating 19. The polymer coating 19 may preferably be made of polyurethane, silicone, Teflon, or Pebax. In addition, the polymer coating 19 may be infused with preventive or other pharmacological compounds, bioactives, or biologics, such as heparin or other drugs. U.S. Publication Number 2013/0060238 entitled “Electrically Charged Medical Device” discloses a medical device with an outer surface prepared to reduce crystalline growth or surface fowling thereon. These features and other features disclosed in U.S. Publication Number 2013/0060238 could be used with the present invention and the disclosure of U.S. Publication Number 2013/0060238 is herewith incorporated in its entirety into this specification. In other embodiments, Heparin may be coated onto the first (or second or both) coiled wire due to the heparin's ability to resist encrustation with long-term implantation of urinary tract medical devices. Fluoropolymers such as PTFE may help to enable the bonding of certain drugs, such as heparin, to the surface of the coils and therefore may be desirable in stents intended for long-term implantation. Other drugs useful for discouraging encrustation may include heparin, covalent heparin, dexamethazone, dexamethasone sodium phosphate, dexamethasone acetate and other dexamethasone derivatives, triclosan, silver nitrate, ofloxacin, ciproflaxin, phosphorylcholine, and triemethoprim. In other embodiments, the polymer coating 19 may be charged to establish a net negative charge on the outer surface of the ureteral stent 1 which is known to minimize encrustation.
In addition, one or more additional medications or drugs may be infused into the polymer coating 19 in order to assist in patient care and comfort. For instance, an antimicrobial drug, such as a combination of rifampin and minocycline, may help to reduce inflammation and microbial activity in the vicinity of the ureteral stent 1. Antimicrobial drugs infused into the polymer coating 19 may include the following drugs, or their salts or derivatives: rifampin, minocycline, a mixture of rifampin and minocycline, a non-steroidal anti-inflammatory agent, a penicillin, a cephalosporin, a carbepenem, a beta-lactam, an antibiotic, an aminoglycoside, a macrolide, a lincosamide, a glycopeptide, a tetracyline, a chloramphenicol, a quinolone, a fucidin, a sulfonamide, a trimethoprim, a rifamycin, an oxaline, a streptogramin, a lipopeptide, a ketolide, a polyene, an azole, an echinocandin, alpha-terpineol, methylisothiazolone, cetylpyridinium chloride, chloroxyleneol, hexachlorophene, chlorhexidine and other cationic biguanides, methylene chloride, iodine and iodophores, triclosan, taurinamides, nitrofurantoin, methenamine, aldehydes, azylic acid, rifampycin, silver, benzyl peroxide, alcohols, carboxylic acids and salts, and silver sulfadiazine. Also useful as antimicrobials are anthracyclines, such as doxorubicin or mitoxantrone, fluoropyrimidines such as 5-fluoroacil, and also podophylotoxins, such as etoposide. The salts and the derivatives of all of these are meant to be included as examples of antimicrobial drugs.
Analgesics, such as aspirin or other non-steroidal anti-inflammatory drugs, may also be infused into the polymer coating 19 to reduce pain and swelling upon implantation of the ureteral stent 1. These drugs or their salts or derivatives may include aspirin and non-steroidal anti-inflammatory drugs, including naproxen, choline, diflunisal, salsalate, fenoprofen, flurbiprofen, ketoprofen, ibuprofen, oxaprozin, diclofenac, indomethacin, sulindac, acetoaminophen, tolmetin, meloxicam, piroxicam, meclofenamate, mefanimic acid, nabumetone, etodelac, keterolac, celecoxib, valdecoxib, rofecoxib, mixtures thereof, and derivatives thereof.
Other analgesics or anesthetics that may be infused into the polymer coating 19 include opioids, synthetic drugs with narcotic properties, and local anesthetics to include at least paracetamol, bupivacaine, ropivacaine, lidocaine, novacaine, alfentanil, buprenorphine, carfentanil, codeine, codeinone, dextropropoxyphene, dihydrocodeine, endorphin, fentanyl, hydrocodone, hydromorphone, methadone, morphine, morphinone, oxycodone, oxymorphone, pethidine, remifantanil, sulfentanil, thebaine, tramadol, mixtures thereof, and derivatives thereof.
Any of these drugs and coatings may preferably be applied in a time-release manner so that the beneficial effect of the drug may be sustained over a period of at least several weeks or months. This may be especially helpful in the case where the ureteral stent 1 will remain in place for a considerable length of time.
The plurality of apertures 9 may be located within one of more of the distal end portion 3, the proximal end portion 5, and the central portion 7 of the ureteral stent 1. Each of the plurality of apertures 9 may pass through the polymer coating 19, the first coiled wire 15, the second coiled wire 17, and into the second lumen 11. Fluid, such as urine or bile, may flow through the plurality of apertures 9 and into the second lumen 11. The plurality of apertures 9 may be produced by means of a laser burn through the polymer coating 19, the first coiled wire 15, and the second coiled wire 17. The plurality of apertures 9 in each layer (the polymer coating 19, the first coiled wire 15, the second coiled wire 17) may be burnt at the same time or at separate times. Other methods known to produce the plurality of apertures 9, such as drilling, may be used.
In
In
The inner coiled wire 17a may define a distal end portion 3, a proximal end portion 5, and a central portion 7 between the two end portions 3, 5, which may be aligned with the respective distal and proximal end portions 3, 5 and central portion 7 of the outer sleeve 15a. The inner coiled wire 17a may define a second lumen 11 therewithin.
The outer sleeve 15a and inner coiled wire 17a may be secured together such that substantially all of an outer surface 25 of the inner coiled wire 17a may contact substantially all of an inner surface 23 of the outer sleeve 15a so that the inner coiled wire 17a may be fixedly retained within first lumen 21. In the context of the outer surface 25 of the inner coiled wire 17a contacting the inner surface 23 of the outer sleeve 15a, “substantially” is defined as at least 75% of the surface area of the outer surface 25 of the inner coiled wire 17a contacting the inner surface 23 of the outer sleeve 15a. The outer sleeve 15a and inner coiled wire 17a may be longitudinally fixed together. The outer sleeve 15a and inner coiled wire 17a may be fixed together with one or more weld beads, mechanical fasteners, adhesives, press fit, or by other methods known to fix similar materials together. In some embodiments, the inner coiled wire 17a may be a flat wire or a round wire. In some embodiments, the inner coiled wire 17a may be hollow.
An outer surface of the outer sleeve 15a may be coated, such as with a fluoropolymer or other protective, lubricious coating, to produce a polymer coating 19. The polymer coating 19 may preferably be made of polyurethane, silicone, Teflon, or Pebax. In addition, the polymer coating 19 may be infused with preventive or other pharmacological compounds, bioactives, or biologics, as described above.
The plurality of apertures 9 may be located within one of more of the distal end portion 3, the proximal end portion 5, and the central portion 7 of the ureteral stent 1. Each of the plurality of apertures 9 may pass through the polymer coating 19, the outer sleeve 15a, the inner coiled wire 17a, and into the second lumen 11. Fluid, such as urine or bile, may flow through the plurality of apertures 9 and into the second lumen 11. The plurality of apertures 9 may be produced by means of a laser burn through the polymer coating 19, the outer sleeve 15a, and the inner coiled wire 17a. The plurality of apertures 9 in each layer (the polymer coating 19, the outer sleeve 15a, the inner coiled wire 17a) may be burnt at the same time or at separate times. Other methods known to produce the plurality of apertures 9, such as drilling, may be used.
In
While the present stent may be highly useful for drainage of the kidneys, similar stents may be used in other hollow parts of the body. These may include biliary or gall bladder stents, stents for use in percutaneous nephrostomy procedures, hepatic drainage, gastrointestinal drainage, and so on, for drainage of other body cavities. It is intended that the foregoing detailed description be regarded as illustrative rather than limiting, and that it be understood that it is the following claims, including all equivalents, that are intended to define the spirit and scope of this invention.
This invention claims the benefit of priority of U.S. Provisional Application Ser. No. 62/102,697, entitled “Ureteral Stent with Sideports,” filed Jan. 13, 2015, which is hereby incorporated by reference in its entirety.
Number | Date | Country | |
---|---|---|---|
62102697 | Jan 2015 | US |